FibroBiologics (FBLG) and Charles River Laboratories (CRL) said Friday they have set up a master services agreement to make FibroBiologics' fibroblast-based CYWC628 for a diabetic foot ulcer trial expected to start next year.
FibroBiologics is assessing the potential treatment of chronic diseases using fibroblasts, the companies said, adding indications being evaluated include: wound healing, multiple sclerosis, degenerative disc disease, psoriasis, thymic involution reversal, as well as cancer.
Charles River will be the contract development and manufacturing organization that will make the drug products for FibroBiologics' upcoming study, the companies said.
Financial details weren't provided.
Price: 3.4500, Change: +0.13, Percent Change: +3.92
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。